Trials / Completed
CompletedNCT00067301
PUFA Augmentation in Treatment of Major Depression
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH) · NIH
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.
Detailed description
As per brief summary
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Polyunsaturated Fatty Acids (PUFA) | |
| DRUG | Citalopram |
Timeline
- Start date
- 2003-09-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2003-08-15
- Last updated
- 2008-01-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00067301. Inclusion in this directory is not an endorsement.